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ABSTRACT
Apoptosis induction has emerged as a treatment option for anticancer therapy. 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a type II 
transmembrane protein, is a potent and specific pro-apoptotic protein ligand, which 
activates the extrinsic apoptosis pathway of the cell death receptors. Here we describe 
the construction and characterization of a new soluble TRAIL, sfTRAIL, stabilized 
with the trimerization Foldon domain from the Fibritin protein of the bacteriophage 
T4. Supernatants of 0.22 μM-filtered supernatants were produced in Vero-transduced 
cells with HSV1-derived viral amplicon vectors. Experiments were undertaken in two 
known TRAIL-sensitive (U373 and MDA.MB.231) and two TRAIL-resistant (MCF7 and 
A549) cell lines, to determine (i) whether the sfTRAIL protein is synthetized and, 
(ii) whether sfTRAIL could induce receptor-mediated apoptosis. Our results showed 
that sfTRAIL was able to induce apoptosis at concentrations as low as 1899.29 pg/
mL (27.71 pM), independently of caspase-9 activation, and reduction in cell viability 
at 998.73 fM.
INTRODUCTION
Apoptosis induction has emerged as a treatment 
option in anticancer therapy. Different from non-apoptotic 
forms of cell death, apoptosis does not result in the 
release of cellular pro-inflammatory molecules into the 
tumor microenvironment, which may lead to further 
tissue damage [1]. Apoptosis is initiated by two different 
mechanisms: the death receptor-mediated (extrinsic 
pathway) and the mitochondria-triggered one (intrinsic 
pathway). Over the last decade, activation of extrinsic 
pathway of apoptosis has been considered an attractive 
therapeutic strategy to promote apoptosis of tumor cells 
[2–4]. Among the death receptors explored for cancer 
treatment, receptors belonging to the pro-apoptotic 
pathway of the TNF-related apoptosis-inducing ligand 
(TRAIL) has gained interest and even entered in clinical 
trials in combination with cytotoxic chemotherapy.
Tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL), a type II transmembrane protein is a 
potent and specific pro-apoptotic protein ligand, able 
to bind to five different receptors. Upon trimerization, 
TRAIL promotes apoptosis by binding to their effector 
death receptors, TRAIL-R1 and TRAIL-R2, triggering 
the recruitment of the adaptor molecule Fas-associated 
death domain and procaspase 8 to the cytoplasmic death 
domain of the receptor [5, 6]. Activated caspase-8 then 
cleaves caspase-3, which in turn promotes cleavage of 
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critical downstream cellular proteins, finally leading 
to DNA fragmentation and cell death. Decoy receptor 
1 (TRAIL-R3), decoy receptor 2 (TRAIL-R4) and the 
soluble receptor osteoprotegerin lack active cytoplasmic 
death domains, blocking the apoptotic machinery [7].
TRAIL-induced apoptosis leaves non-tumoral 
cells unharmed, underlying its potential as a candidate 
therapeutic protein in the carcionogenesis cascade [2, 8]. 
While this oncotargeted potential is poorly understood, it 
has made TRAIL pathway an attractive target for cancer 
treatment, leading to the development of clinical trials of 
recombinant human TRAIL proteins. Among the tumor 
types already tested in clinical trials, Non-Small Cell 
Lung Cancer (Phase II), Colorectal Cancer (Phase I) and 
Non-Hodgkin’s Lymphomas (Phase I). Although, despite 
the therapeutic potential of cell death receptor agonists 
already tested in preclinical models, the translation of 
these effects into the clinic remains disappointing, mainly 
due to protein instability and high cost of production. 
Here, we describe the construction and characterization 
of a novel recombinant soluble TRAIL protein, named 
sfTRAIL stabilized with the trimerization Foldon domain, 
showing its capabilities of inducing robust apoptosis, even 
at picomolar concentrations.
RESULTS
Expression of TRAIL receptors
We further determined the expression of TRAIL 
receptors, TRAIL-R1 and TRAIL-R2, in A549, MCF7, 
U373 and MDA.MB.231 cell lines by flow cytometry 
(Supplementary Figure 1). Resistance/sensitivity to 
TRAIL-mediated apoptosis was previously described for 
these cell lines [9–12]. Both sensitive cell lines (U373 and 
MDA.MB.231) showed higher expression of TRAIL-R1 
and TRAIL-R2 than the MCF7 cell line. Interestingly, the 
A549 cell line showed high expression of both TRAIL 
receptors.
Sensitivity to rhTRAIL induced apoptosis
In order to analyze the sensitivity and resistance 
of cell lines to TRAIL induced apoptosis, commercially 
available rhTRAIL was used (Supplementary Figure 2). 
Both TRAIL-sensible cell lines, U373 and MDA.MB.231 
showed an increased apoptosis, when compared to control 
groups. Interestingly, MCF7 cell line also showed an 
increase in apoptosis. Only A549 cell line showed no 
effect when exposed to rhTRAIL.
Expression of sfTRAIL
In silico protein mass analysis (http://web.expasy.
org/compute_pi/) indicates that the sfTRAIL protein 
constructed had a 22845.66 Da mass. To detect the 
sfTRAIL protein expression, we initially transduced Vero 
cells with pA.EUA1 or pA.sfTRAIL amplicon vectors. As 
expected, western blot results showed a band of ~22 KDa, 
which represents the monomeric form of the sfTRAIL 
protein (Figure 1).
Quantification of sfTRAIL in pA.sfTRAIL 
transduced Vero cells
Secretion of sfTRAIL protein was quantified 
by ELISA, in Vero cells transduced with pA.EUA1 or 
pA.sfTRAIL amplicon vector at MOI1. Subconfluent 
Vero cells were transduced in T75 cell culture flask with 
pA.EUA1 or pA.sfTRAIL amplicon vectors, at MOI1. 
Transduced Vero cell lines were able to produce filtered 
supernatants (SN) with a concentration of up to 1899.29 
pg/mL (27.71 pM), which was the highest sfTRAIL 
production ever obtained by this method. Despite the 
concentration produced by this approach (about 2 ng/mL) 
not being enough for in vivo pre-clinical or clinical testing, 
it was sufficient for the cell culture assays performed, as 
shown below. Supernatants from pA.EUA1-transduced 
Vero cells were used as negative control, with undetectable 
production of TRAIL protein (Supplementary Figure 3).
Bystander effect of sfTRAIL protein
Next, we evaluated the capability of apoptosis 
induction of the sfTRAIL protein, using conditioned 
media from pA.sfTRAIL-transduced Vero cells described 
above, which sfTRAIL concentration was 1899.29 pg/
mL (27.71 pM). Supernatants from pA.EUA1-transduced 
Vero cells were used as negative control. The MTS assay 
showed a statistically different viability reduction in both 
TRAIL-sensitive cell lines, U373 (p-value=0.0016) and 
MDA.MB.231 (p-value<0.0001), treated with sfTRAIL-
containing supernatants (Figure 2). Statistical differences 
were not observed for TRAIL-resistant cell lines, A549 
and MCF7.
Apoptosis induction of sfTRAIL protein
We further investigated the sfTRAIL protein pro-
apoptotic properties. We also analyzed caspase-9 cleavage, 
which is one of the molecular components of the intrinsic 
mitochondrial apoptosis pathway, using filtered conditioned 
media from Vero transduced cells (Figure 3). Western 
blot analysis indicates cleavage of pro-caspase 8, pro-
caspase 3 and PARP, upon induction with 0.22 μm-filtered 
conditioned media, produced in Vero cells transduced with 
pA.EUA1 or pA.sfTRAIL (1899.29 pg/mL; 27.71 pM). As 
expected, cleavage of pro-caspase 9 was not observed at 
these time points. In this way, sfTRAIL apoptosis induction 
rapidly activates the extrinsic apoptosis pathway, in TRAIL-
sensitive cell lines, as early as 2 hours after sfTRAIL 
induction. We also observed a cleavage of caspase-9 in the 
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MDA.MB.231 cell line treated with sfTRAIL-containing 
supernatants, which is consistent with its type II apoptotic 
behavior. We found that, sfTRAIL protein behaves as 
expected, promoting apoptosis at concentrations of no more 
than 2 ng/mL, in the sensitive cell lines used, but not in 
the resistant ones. At this point, it is worth to recall that 
we decided to include the analysis of caspase-3 cleavage in 
the MCF-7 cell line, despite the fact this cell line does not 
express this protein.
Bystander effect of sfTRAIL protein at 
femtomolar concentrations
Next, we evaluated the ability to reduce cell viability 
of the sfTRAIL protein at femtomolar concentrations, 
using conditioned media from pA.sfTRAIL-transduced 
Vero cells described above, which sfTRAIL concentration 
was in mean 78.32 pg/mL. Supernatants from non-
transduced cells (NTC) and pA.EUA1-transduced Vero 
cells were used as negative control. After 72 hours of 
incubation with conditioned supernatants, MTS assay 
showed a statistically different viability reduction 
(p-value=0.0032 or p-value<0.0001, depending on the 
supernatant stock used) in the U373 (TRAIL-sensitive) 
for all three protein productions, while the A549 (TRAIL-
resistant) cell line did not respond to the sfTRAIL 
challenge (Figure 4). Thus, considering a trimeric 
sfTRAIL mass of 68.53698 KDa and a concentration of 
68.45 pg/mL (sfTRAIL stock B), the sfTRAIL protein 
induced a decrease in cell viability at a concentration of 
998.73 fM in U373 cells.
Reproducibility of sfTRAIL protein production
In order to address the consistency between 
each sfTRAIL protein production, we transduced 
Vero cells with a EGFP-expressing amplicon control 
vector or the sfTRAIL-expressing amplicon vector 
in a biological triplicate. Transductions were done at 
MOI0.1. As a result, after the ELISA quantification 
we obtained sfTRAIL protein supernatants with a 
mean concentration of 78.32 pg/mL (Table 1 and 
Supplementary Figure 4). Variation between the three 
independent sfTRAIL protein productions was minimal, 
demonstrating a good reproducibility in the sfTRAIL 
production approach.
Figure 1: (A) Schematic representation of the sfTRAIL protein; (B) Western blot analysis of sfTRAIL protein expression. Vero cells were 
transduced with pA.EUA1 or pA.sfTRAIL amplicon vectors, at MOI1. Anti-TRAIL antibody and anti-β-actin were used.
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DISCUSSION
The use of soluble TRAIL has been pronounced as 
an ideal therapeutic molecule exhibiting a selective and 
potent antitumor effect [8]. TRAIL-induced apoptosis 
leaves non-tumoral cells unharmed, underlying its 
potential as a therapeutic protein in oncology treatment. 
While this oncotargeted potential is poorly understood, 
it has encouraged the development of clinical trials of 
recombinant human TRAIL proteins. Among the tumor 
types already tested in clinical trials, Non-Small Cell 
Lung Cancer (Phase II), Colorectal Cancer (Phase I) and 
Non-Hodgkin’s Lymphomas (Phase I). However, the 
instability of TRAIL protein and its high cost constitute 
major drawbacks to its clinical use.
Soluble TRAIL (sTRAIL) stabilization as 
a trimer is essential for its binding to the effector 
TRAIL receptors, TRAIL-R1 and TRAIL-R2, even if 
expression of both TRAIL receptors were not described 
as predictors of TRAIL response [13, 14]. Several 
versions of recombinant soluble TRAIL with different 
N-terminal fusions domains have been reported [15–18]. 
Most TRAIL clinical trials use a non-tagged version, 
containing amino acids 114–281, stabilized by the 
addition of zinc and reducing agent to the cell-culture 
media and extraction buffers, and by formulation of 
the purified protein at neutral pH [19]. These further 
modifications increases the production steps and time, 
and may explain the high cost of the therapeutic protein. 
In addition, further modifications may affect the pro-
apoptotic capabilities of the resulting trimer, requiring 
high drug concentrations.
To our knowledge, this is the first study describing 
the stabilization of TRAIL protein with a synthetic 
N-terminal fusion domain based on the C-terminal 
Foldon domain of the Fibritin T4 bacteriophage. This 
recombinant protein (sfTRAIL) was produced in cell 
culture supernatants of transfected/transduced Vero cells. 
Although Vero cells are not ideal for secreted recombinant 
protein production, this approach allowed a rapid proof-
Figure 2: Cell viability (MTS) of cells incubated with sfTRAIL supernatants. Values shown are the mean value (± SDs) 
of triplicates. (SN) means supernatants. sfTRAIL concentration in supernatants was 1899.29 pg/mL. Data represents three experiments 
performed in triplicate. p-value were assessed by Student’s t-test.
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of-concept validation. Therefore, it is worth to note that 
sfTRAIL protein concentration may be further improved.
Regardless of the amount of protein produced, 
sfTRAIL protein was able to induce apoptosis at 
picomolar concentrations, and reduction in cell viability 
at femtomolar concentrations, without any special 
biochemical stabilization requirement. In this work, 
we produced recombinant TRAIL proteins simple by 
filtering cell culture supernatants. This may represent a 
major advantage over currently used recombinant TRAIL 
proteins available, even reducing its toxic side effects and 
improving patient outcome. Bioactive concentrations of 
current available soluble TRAIL variants are usually tested 
at concentrations of ng/mL or even μg/ml [10, 20–22].
Figure 3: Western blot analysis of sfTRAIL-mediated apoptosis induction. sfTRAIL-mediated apoptosis induction of 
A549, MCF7, U373 and MDA-MB-231 cells, cultured in conditioned media, at 2h, 4h and 8h post-induction (PI). UTC, 
untreated control.
Figure 4: Cell viability (MTS) of cells incubated with sfTRAIL supernatants. Values shown are the mean value (± SDs) of three 
experiments performed in triplicate (Stock A, B and C). (SN) means supernatants; NTC (SN) represents supernatants of non-
transduced cells; * indicates p-value (Student’s t-test), where ** means p-value=0.0032 and *** p-value<0.0001.
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The antitumor capabilities of the recombinant 
TRAIL variants here described were tested in four 
cancer cell lines with known TRAIL-sensitivity/
resistance profiles, A549 (resistant), MCF7 (moderate-
sensitive), U373 (sensitive) and MDA.MB.231. 
Although the MCF7 cell line was previously described 
as resistant, in our work it showed moderate sensitivity 
[10, 23]. So far, the bystander effect, transferred in the 
conditioned medium, was observed in the U373, MDA.
MB.231 and MCF7 cell lines, not affecting the A549 
cell line.
In conclusion, we showed that sfTRAIL protein 
exhibit a potent pro-apoptotic effect, triggering cell 
death at pico and femtomolar concentrations. In 
addition, as it is not necessary to further purify the 
supernatants, its low production requirement should 
reduce its final cost.
MATERIALS AND METHODS
Cell culture
Vero (African green monkey kidney), Vero-7b 
(Vero-derived cell line expressing ICP4/ICP27) [24], 
Gli36 (glioblastoma) were kindly provided by Dr. Alberto 
Epstein [25]. A549 (lung cancer) cell line was obtained 
from ECACC. Jurkat (leukemia), MCF7 (breast cancer), 
MDA.MB.231 (breast cancer) and HeLa (cervical cancer) 
cell lines were obtained from ATCC. U373 (glioma) 
cell line was kindly given by Dr. Joseph Costello. Cell 
lines were cultured in Dulbecco’s minimum essential 
medium (DMEM; Invitrogen, USA) supplemented with 
10% fetal bovine serum (FBS; Invitrogen, USA), and 1% 
antibiotic-antimycotic solution (Invitrogen, USA). Vero-
7b cells were selected with 1 mg/mL of G418 (Sigma-
Aldrich, USA) at every three passages. All cell lines were 
maintained in a humidified 37°C atmosphere of 95% air 
and 5% CO2.
Cell line authentication
Authentication of A549, MCF7, U373 and MDA.
MB.231 cell lines was performed by short tandem 
repeat (STR) DNA typing according to the International 
Reference Standard for Authentication of Human Cell 
Lines using a panel of 8 (D5S818, D13S317, D7S820, 
D16S539, vWA, TH01, TPOX and CSF1P0) STR 
loci plus gender determination (AMEL), using the 
fluorescent labeling primers as reported by Dirks et al 
[26]. Briefly, 50ng of DNA was amplified in a multiplex 
PCR reaction carried out in a total volume of 10uL with 
the Qiagen multiplex kit (Qiagen) comprising 0.5 μM of 
all fluorescent primer pairs plus 1 μM of TH01 primer 
reinforcement. DNA amplification products were 
diluted 1:100 in ultrapure nuclease free water (USB, 
Cleveland, USA) and combined with 0.3 μL of the 
internal size standard 500ROX (Applied Biosystems, 
Foster City, CA, USA) in 8.7 μL of formamide and 
loaded automatically in a capillary electrophoresis 
system using the Genetic Analyzer ABI PRISM 3500 
(Applied Biosystems). The analysis was performed 
in the GeneMapper software version 4.1 (Applied 
Biosystems). Genotyping confirmed the identity of 
all cell lines, with the exception of U373, which was 
shown to be a sub-clone of U251 cell line.
Plasmid construction
cDNA from Jurkat cells was used to amplify the 
extracellular domain of the human TRAIL (aa 114-281). 
Total RNA was obtained from 1×106 cells and converted 
in cDNA using RevertAid H Minus Reverse Transcriptase 
(Thermo Scientific) and oligo(dT)18 primer. The resulting 
cDNA was subsequently PCR amplified with the Phusion 
High-Fidelity DNA Polymerase (Thermo Scientific) 
using the primers sTRAIL_F and sTRAIL_R (Table 1) 
and the 550 bp PCR fragment was gel-purified, digested 
with EcoRI (Thermo Scientific) and ligated with T4 DNA 
ligase (Thermo Scientific) at the EcoRI restriction site 
of pCI.Neo plasmid (Promega), generating the pCI.Neo.
sTRAIL plasmid.
The coding sequence of the Fibritin foldon domain, 
of the T4 Bacteriophage, was humanized using Sequence 
Manipulation Suite [27]. Both Foldon_F and Foldon_R 
ssDNA oligos were hybridized and ligated into the NheI 
site of pCI.Neo.sTRAIL, with T4 DNA ligase (Thermo 
Scientific). The resulting plasmid, named pCI.Neo.
sfTRAIL, was sequenced to confirm the correct fusion 
gene structure. Escherichia coli DH5α cells (New England 
Biolabs, USA) were used for cloning experiments and 
plasmid propagation. Bacterial strains were routinely 
Table 1: ELISA quantification of sfTRAIL protein 












A, B and C identify the biological triplicate of the experiment
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grown at 37°C in Luria-Broth (Sigma-Aldrich) or LB-agar 
(Sigma-Aldrich) containing medium and supplemented 
with 100 μg/mL ampicillin (Sigma).
HSV-1-derived amplicon vector production
Amplicon plasmid pA.EUA1 [28] containing one 
HSV-1 replication origin and one HSV-1 package signal 
“a” was used to derive the pA.sfTRAIL amplicon plasmid. 
Firstly, pCI.Neo.sfTRAIL was digested with AseI and DraI 
(New England Biolabs), generating an 1804 bp fragment. 
After being blunt-ended with the Klenow enzyme 
(Thermo Scientific), this 1804 bp AseI/DraI fragment 
was subcloned into the SnaBI (New England Biolabs) site 
of the pA.EUA1 plasmid. The resulting plasmid, named 
pA.sfTRAIL, was used to produce amplicon vectors, as 
described below.
The defective cre-loxP-based helper virus, HSV-1 
LaLΔJ [25] was used as helper to produce amplicon vectors 
that were propagated and titrated in Vero-7b cells. Amplicon 
vector stocks were produced in T25 flasks containing 3×106 
Vero-7b cells, previously transfected with pA.EUA1 or 
pA.sfTRAIL plasmids, infected at multiplicity of infection 
(MOI) of 0.1 plaque forming unit (PFU)/cell in Medium 
199 (Invitrogen, USA) supplemented with 1% FBS (M199 
1% FBS). When complete cytophatic effect (CPE) was 
observed (48~72 h post-infection), viruses were harvested. 
Thus, infected cells were centrifuged at 1,000 × g for 10 min 
at 4°C. The formed pellet was diluted in 400 μL of M199 
1% FBS and frozen/thawed three times to break down the 
infected cells and facilitate the viral particles release. The 
pellet solution was clarified at 1,000 × g for 10 min at 4°C, 
aliquoted and stored at -80°C until use. Amplicon/helper 
particles were tittered by plaque assay [25] in Gli36 and 
Vero-7b cells respectively.
Western blot analysis
Vero cells were seeded in 6 well plate at a density 
of 5×105 cells per well. Twenty-four hours later, cells 
were transduced with pA.EUA1 or pA.sfTRAIL 
amplicon particles at MOI1. After 48 h, supernatants 
and cells were collected separately. Supernatants were 
filtered in 0.22 μm filters. Cells were rinsed in ice-cold 
PBS then scraped and lysed in lysis buffer (50mM Tris 
pH7.6–8, 150mM NaCl, 5mM EDTA, 1mM Na3VO4, 
10mM NaF, 10mM sodium pyrophosphate, 1% NP-
40, and protease cocktail inhibitors). Western blotting 
was performed using standard SDS-PAGE gel, loading 
20 μg of protein per lane. The antibodies used were: 
rabbit polyclonal anti-TRAIL (abcam, #ab2056), rabbit 
monoclonal anti-caspase 8 (Cell Signaling, #4790), rabbit 
polyclonal anti-caspase 3 (Cell Signaling, #9662), mouse 
monoclonal anti-caspase 9 (Cell Signaling, #9508), 
rabbit polyclonal anti-PARP (Cell Signaling, #9542) and 
β-actin (Cell Signaling, #3700). After incubation with the 
appropriate horseradish peroxidase (HRPO)-conjugated 
secondary antibody (Cell Signaling, dilution 1:5000), the 
immunoreactivity was visualized by chemiluminescence 
(Amersham ECL Western Blotting Detection Reagent, 
GE Healthcare).
Electroporation
Electroporations of 8 × 106 HeLa cells were carried 
out with two pulses of 200 V and 850 μF, in 2 mm cuvettes, 
using Gene Pulser II (Bio-rad). Electroporated cells were 
seeded in T75 cell culture flasks and further maintained in a 
humidified 37°C atmosphere with 5% CO2. After 48 hours 
of incubation, supernatants were cleared by centrifugation 
followed by filtration with 0.22 μm filters and stored at 4°C.
ELISA protein quantification
sfTRAIL protein contained in filtered supernatants 
were quantified by ELISA, using Human TRAIL/
TNFSF10 Quantikine ELISA kit (R&D Systems, 
Minneapolis, MN, USA), following the manufacturer’s 
instructions. Serially diluted rhTRAIL (R&D Systems, 
Minneapolis, MN, USA) was used for indirect 
quantification. It is worth to note that along the 
experiments, sfTRAIL protein was produced in two 
opportunities. Protein quantification was performed by 
ELISA at each sfTRAIL production.
Cell viability assay
To determine the effect of sfTRAIL protein in 
cellular viability over time, A549, MCF7, MDA.MB.231 
and U373 cells were seeded into 96-well plates, at a 
concentration of 5 × 103 cells per well, as previously 
described [29]. After 24 hours, cells were cultured in 
0.22 μm-filtered conditioned media. After 48 hours of 
incubation, viable cells were quantified using MTS assay 
(CellTiter 96® AQueous One Solution Cell Proliferation 
Assay, Promega). Assays were performed in triplicate and 
repeated three times. In order to analyze the stability of the 
sfTRAIL protein, filtered supernatants were maintained at 
4°C during 60 days, without any conservator. After this 
period, all four cell lines were rechallenged to TRAIL 
induced apoptosis and assayed by MTS analysis.
Apoptosis and TRAIL receptors detection by 
flow cytometry
For apoptosis analysis, cells were incubated with 
rhTRAIL (R&D Systems, Minneapolis, MN, USA) at 100 
ng/mL for 4 hours. After incubation, cells were washed in 
cold PBS and apoptosis was assessed by flow cytometry 
using the Annexin V-PE/7-AAD apoptosis detection 
kit (BD Biosciences), according to the manufacturer’s 
protocol. Briefly, 105 cells in 100 μL of 1x binding buffer 
were incubated with 5 μL Annexin V-PE and 5 μL 7-AAD 
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reagent for 15 minutes, at room temperature in the dark. 
After incubation 400 μL of 1x binding buffer were added 
and tubes were directly analyzed in a FACS Aria II (BD 
Bioscience).
Expression of TRAIL receptors was also evaluated 
by flow cytometry. Thus, incubation with antibodies was 
performed as described above, using human anti-DR4-PE 
(R&D Systems - Clone 69036) and anti-DR5-PE (R&D 
Systems - Clone 71908) antibodies. Non-stained cells 
were used as controls, setting gates at 1% positivity for 
comparisons.
Statistical analysis
The differences between groups were evaluated by 
calculating Student’s t-test, one-way ANOVA with post 
hoc comparison Tukey’s test. For all tests, p-value < 0.05 
were considered statistically significant.
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